camptothecin has been researched along with palbociclib in 5 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 3 (60.00) | 24.3611 |
| 2020's | 2 (40.00) | 2.80 |
| Authors | Studies |
|---|---|
| Jadhav, A; Kerns, E; Nguyen, K; Shah, P; Sun, H; Xu, X; Yan, Z; Yu, KR | 1 |
| Kabir, M; Kerns, E; Nguyen, K; Shah, P; Sun, H; Wang, Y; Xu, X; Yu, KR | 1 |
| Kabir, M; Kerns, E; Neyra, J; Nguyen, K; Nguyễn, ÐT; Shah, P; Siramshetty, VB; Southall, N; Williams, J; Xu, X; Yu, KR | 1 |
| Dicker, DT; El-Deiry, WS; Zhang, J; Zhao, S; Zhou, L | 1 |
| Dixon, JM; Gray, M; Kay, C; Martínez-Pérez, C; Meehan, J; Turnbull, AK; Webber, V | 1 |
1 review(s) available for camptothecin and palbociclib
| Article | Year |
|---|---|
Current trends in the treatment of HR+/HER2+ breast cancer.
Topics: Antineoplastic Combined Chemotherapy Protocols; Breast; Breast Neoplasms; Camptothecin; Chemotherapy, Adjuvant; Clinical Trials as Topic; Estrogen Receptor Antagonists; Female; Humans; Immunoconjugates; Mastectomy; Molecular Targeted Therapy; Neoadjuvant Therapy; Piperazines; Progression-Free Survival; Protein Kinase Inhibitors; Pyridines; Quinolines; Receptor, ErbB-2; Receptors, Estrogen; Receptors, Progesterone; Trastuzumab | 2021 |
4 other study(ies) available for camptothecin and palbociclib
| Article | Year |
|---|---|
Highly predictive and interpretable models for PAMPA permeability.
Topics: Artificial Intelligence; Caco-2 Cells; Cell Membrane Permeability; Humans; Models, Biological; Organic Chemicals; Regression Analysis; Support Vector Machine | 2017 |
Predictive models of aqueous solubility of organic compounds built on A large dataset of high integrity.
Topics: Drug Discovery; Organic Chemicals; Pharmaceutical Preparations; Solubility | 2019 |
Retrospective assessment of rat liver microsomal stability at NCATS: data and QSAR models.
Topics: Animals; Computer Simulation; Databases, Factual; Drug Discovery; High-Throughput Screening Assays; Liver; Machine Learning; Male; Microsomes, Liver; National Center for Advancing Translational Sciences (U.S.); Pharmaceutical Preparations; Quantitative Structure-Activity Relationship; Rats; Rats, Sprague-Dawley; Retrospective Studies; United States | 2020 |
The CDK4/6 inhibitor palbociclib synergizes with irinotecan to promote colorectal cancer cell death under hypoxia.
Topics: Antineoplastic Agents, Phytogenic; Apoptosis; Camptothecin; Cell Hypoxia; Cell Survival; Colorectal Neoplasms; Cyclin-Dependent Kinase 4; Cyclin-Dependent Kinase 6; Drug Screening Assays, Antitumor; Drug Synergism; Extracellular Signal-Regulated MAP Kinases; Glycogen Synthase Kinase 3 beta; HT29 Cells; Humans; Hypoxia-Inducible Factor 1, alpha Subunit; Inhibitory Concentration 50; Irinotecan; MAP Kinase Signaling System; Piperazines; Protein Stability; Proto-Oncogene Proteins c-akt; Pyridines | 2017 |